| (Values in U.S. Thousands) | Sep, 2023 | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 |
| Sales | 0 | 0 | 0 | 310 | 240 |
| Sales Growth | unch | unch | -100.00% | +29.17% | -20.00% |
| Net Income | -1,980 | -7,380 | 11,400 | -9,250 | -29,210 |
| Net Income Growth | +73.17% | -164.74% | +223.24% | +68.33% | -287.92% |
Baudax Bio Inc (BXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Baudax Bio Inc. is a pharmaceutical company. It is focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. The Company's lead product candidate is a proprietary intravenous form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. Baudax Bio Inc. is based in Malvern, Pennsylvania.